Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.45% |
| 2 | Technology | 16.09% |
| 3 | Consumer Staples | 10.57% |
| 4 | Consumer Discretionary | 9.95% |
| 5 | Communication Services | 9.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EMAN
3301
DELISTED
eMagin Corporation
EMAN
| $79K | ﹤0.01% |
99,800
-168,411
| -63% | -$88.6K |
|
3302
Boxlight
BOXL
$4.54M
| $77K | ﹤0.01% |
58
+46
| +383% | +$52.7K |
|
|
IMV
3303
DELISTED
IMV Inc. Common Shares
IMV
| $77K | ﹤0.01% |
+2,460
| New | +$61.9K |
|
3304
Rekor Systems
REKR
$97.6M
| $76K | ﹤0.01% |
+18,932
| New | +$67.9K |
|
|
NMTR
3305
DELISTED
9 Meters Biopharma
NMTR
| $74K | ﹤0.01% |
6,440
-4,830
| -43% | -$54.5K |
|
|
DNR
3306
DELISTED
Denbury Resources, Inc.
DNR
| $72K | ﹤0.01% |
+261,635
| New | +$78.6K |
|
3307
Avalon Holdings
AWX
$10.9M
| $71K | ﹤0.01% |
44,000
+10,900
| +33% | +$15.8K |
|
3308
SEACOR Marine Holdings
SMHI
$262M
| $70K | ﹤0.01% |
27,546
-10,115
| -27% | -$28.8K |
|
3309
Banco Bradesco
BBDO
$33.4B
| $69K | ﹤0.01% |
24,033
+6,087
| +34% | +$17.4K |
|
3310
Forum Energy Technologies
FET
$927M
| $69K | ﹤0.01% |
6,555
-30,716
| -82% | -$246K |
|
|
JFIN
3311
Jiayin Group
JFIN
$120M
| $69K | ﹤0.01% |
+17,758
| New | +$50.5K |
|
3312
CBAK Energy Technology Ltd
CBAT
$65.5M
| $68K | ﹤0.01% |
88,989
-2,260
| -2% | -$1.19K |
|
|
BDRX
3313
Biodexa Pharmaceuticals
BDRX
$1.61M
| – | – |
0
| – | – |
|
|
CASI
3314
DELISTED
CASI Pharmaceuticals
CASI
| $67K | ﹤0.01% |
+2,680
| New | +$58.2K |
|
3315
CLPS Inc
CLPS
$26.1M
| $67K | ﹤0.01% |
+30,816
| New | +$63.9K |
|
|
PME
3316
DELISTED
Pingtan Marine Enterprise Ltd.
PME
| $66K | ﹤0.01% |
+57,287
| New | +$61.7K |
|
|
KRKR
3317
36Kr Holdings
KRKR
$6.18M
| $64K | ﹤0.01% |
+964
| New | +$82.9K |
|
|
HURA
3318
TuHURA Biosciences
HURA
$146M
| $63K | ﹤0.01% |
52
+45
| +643% | +$57.6K |
|
3319
Ocugen
OCGN
$458M
| $62K | ﹤0.01% |
279,669
-407,845
| -59% | -$123K |
|
|
BSIN
3320
Big Sky Industrial
BSIN
$71.4M
| $62K | ﹤0.01% |
+12,060
| New | +$59.7K |
|
|
GMO
3321
DELISTED
General Moly, Inc.
GMO
| $62K | ﹤0.01% |
306,741
+268,846
| +709% | +$53.2K |
|
3322
Geron
GERN
$982M
| $61K | ﹤0.01% |
+28,176
| New | +$42.1K |
|
|
RKTO
3323
Rocket One Inc
RKTO
$19.3M
| $61K | ﹤0.01% |
+950
| New | +$74.3K |
|
3324
Siebert Financial
SIEB
$78.1M
| $61K | ﹤0.01% |
12,100
+700
| +6% | +$4.42K |
|
3325
Paramount Gold Nevada
PZG
$127M
| $60K | ﹤0.01% |
+48,180
| New | +$51.5K |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 25% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.